Aim: Based on this hypothesis a new biological combination termed V20E immune peptides comprising HIV viral antigen and a non-specific HIV antibodies has been formulated in oral and injectable form for inhibiting or preventing the HIV infection.
Introduction: A new assumption assumes that CD4+ T-cell can induce the production of a pathogenic broadly neutralizing anti-HIV antibodies to mask a proportion of corresponding HIV antigens in immune-complex form (Ag/ nAbs) antigen/neutralizing antibody for a long time preventing its attacks by CD8+ cytotoxic T-cells and anti-viral drugs.
Materials and Methods: A pilot study was carried out on a total of twenty-five patients (21 males, 4 females; aged 28-38 years) all of them were positive for HIV antibodies and divided them into three groups I, II and III, each group included seven patients. Only four HIV-positive plasma patients as control (IV group) were advised to take Antiretroviral drugs (ARVs) and enrolled on to a similar protocol. The groups were classified according to their CD4+, CD8+T-cells count, quantitation of HIV RNA and showed the same clinical symptoms of HIV/AIDS. All the patients wrote consent of acceptance to take the V20E immune peptides combination therapy in the form of S/C Injection or oral capsules for 12 weeks.
Results: Serum samples were collected 3 times for Quantitative measuring of (HIV RNA), circulating immunecomplex (CIC) IC1, IC2, and IC3, CD4+ and CD8+ T-cells count. At the end of this therapy, all of the patient's viral loads had reached under the detectable limits (less than 50 copies/ml); also there were significant Increases of their CD4+ T-cells count.
Conclusion: These results have important implications for the development of real therapeutic and prophylactic vaccine and also raise the great possibility for developing a serological screening method for monitoring HIV infection and the successful treatment.
Published Date: 2019-03-28; Received Date: 2019-03-14